NewsOct 5, 2026
Juvmo (tavapadon) is a once-daily Parkinson's pill, and if an older dopamine agonist has caused you or a family member trouble, it's worth asking your neurologist about. It's the first new class of dopamine drug for Parkinson's in decades. In three phase 3 trials it delivered the motor benefit you'd expect from an agonist, with very low rates of the compulsive gambling, sudden sleep, and leg swelling that push so many patients off pramipexole and ropinirole. It's the first agonist in a long time that most patients might be able to stay on.
Eye HealthOct 5, 2026
A six-month wet AMD shot is close but not here yet. Zenkuda, a new anti-VEGF drug from Kodiak Sciences, matched Eylea for vision gains in a Phase 3 trial with more than half of patients dosed only every six months. The results come from a company press release and haven't been peer reviewed, and the drug isn't FDA-approved yet. But for anyone worn out by the frequent injections of wet AMD care, this is the first Phase 3 result showing a majority of patients can hold their vision on a shot every six months.
NewsOct 5, 2026
If you have a fever or real pain in pregnancy, acetaminophen at the lowest dose that works, for as short a time as you need, is still the safest treatment. The strongest evidence to date does not show it raises your child's risk of autism or ADHD. The FDA's September 2025 warning set off the alarm, but the largest sibling-matched studies and a BMJ umbrella review published since do not back the causal link it flagged. The higher risk older cohorts saw seems to track with something families share.
MedicationOct 5, 2026
Emcitate (tiratricol) is now the first FDA-approved drug for MCT8 deficiency. It's a daily oral tablet that lowers the toxic T3 flooding the heart, muscles, and liver of a boy born with this X-linked disease, and in trials it slowed the wasting and tachycardia that have driven early death. It doesn't cure the severe brain and motor disability that defines the syndrome, but it changes what families can do about the body-wide part of the disease. The earlier a family reaches diagnosis and starts dosing, the more of that benefit stays with the child.
NewsOct 5, 2026
Camzyos (mavacamten), a daily pill, eased the blocked outflow from the heart in teenagers with symptomatic obstructive hypertrophic cardiomyopathy (HCM), much as it does in adults. In the trial that got it approved, no adolescent's pumping function fell below the safety threshold. If the next conversation at your teen's HCM clinic has been about septal myectomy or alcohol ablation, the pill is now an FDA-approved alternative to raise. The approval rests on one small trial that lasted 28 weeks, so how teens do on the drug over years is still unknown.
NewsOct 5, 2026
Survodutide's first Phase 3 trial in type 2 diabetes posted up to 13% weight loss in people who stayed on the drug. On paper, that makes it competitive. But the comparisons are cross-trial, far more patients stopped the drug for side effects than on placebo, and no regulator has approved it anywhere. For now, an approved drug like semaglutide or tirzepatide is the one that can help you this year.
NewsOct 5, 2026
If your chlorthalidone bottle shows lot RISA24001, RISB24002, or RISA24002 with an April 2027 expiration, it is on the FDA recall list and should be swapped this week. Any other bottle is fine. The problem is that the tablets may not fully dissolve, so they can act weaker than the label says. Don't stop taking the pill while you sort this out, because interrupting blood pressure therapy is linked to a measured increase in stroke and heart attack risk.
NewsOct 5, 2026
Pirtobrutinib (Jaypirca) is now approved as a first-line daily pill for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as long as the cancer doesn't carry a 17p chromosome deletion. The FDA cleared it on October 2, 2026. The trial behind the approval showed striking disease control versus chemotherapy, and a separate head-to-head against ibrutinib found it at least as effective and easier on the heart. But no trial has yet tested it against the two second-generation BTK pills most oncologists now reach for first.
MedicationSep 28, 2026
They can be, if nutrition checks start with the first dose and not months later. In a new study of US kids and teens starting these drugs, about 1 in 6 had a new deficiency diagnosed within a year, mostly low vitamin D. That sounds like the drug drains vitamins. The study can't show that. Many kids with obesity start out low, the drug cuts how much they eat, and almost none got nutrition counseling early enough to catch it.
MedicationSep 26, 2026
Yes, in a large UK real-world analysis presented at the 2026 European Respiratory Society Congress, adults on semaglutide had about 40% fewer asthma attacks and 20% fewer COPD flare-ups than adults on an older diabetes pill. Six years of similar cohort work points the same way. It isn't yet a lung treatment: no randomized trial has tested semaglutide with asthma or COPD as its main endpoint, and no respiratory guideline endorses it. But if you already qualify for semaglutide for weight or diabetes and you have asthma or COPD, that possible bonus is now worth raising with the doctor who manages your lungs.
MedicationSep 25, 2026
Only if your bottle is Vitruvias Thyroid Tablets USP 30 mg, lot 504950. Any other lot, any other brand, or any synthetic levothyroxine is untouched. The twist is that these tablets may be too strong, not too weak, so the risk is drug-induced hyperthyroidism rather than the more familiar undertreatment. Don't stop the pill on your own. Call your prescriber the same day for a replacement, and watch for a racing heart, tremor, or unexplained weight loss in the meantime.
NewsSep 17, 2026
Maybe, eventually. Teva reported that a single injection of an anti-IL-15 antibody partly protected the intestinal lining of adults who ate gluten daily for six weeks. On biopsy, the treated group lost about half as much villous height relative to crypt depth as placebo. That clears a bar the previous anti-IL-15 drug missed. But it's sponsor-reported topline data from a small study, not a published trial, not an approval, and not a reason to relax the diet.
NewsSep 8, 2026
If you're on a first-line aromatase inhibitor plus a CDK4/6 inhibitor for HR-positive, HER2-negative metastatic breast cancer, there's a new option worth understanding. On September 4, 2026, the FDA approved camizestrant (Etcamah) as the first cancer therapy triggered by a blood test rather than a growing tumor on a scan. In the trial that won it approval, switching the moment an ESR1 mutation appeared in the blood roughly doubled the time before the cancer advanced. Whether it also extends life is what the next few years of follow-up will answer.
NewsSep 4, 2026
On September 3, 2026, the FDA approved Zanvastro (zilganersen), the first drug shown in a controlled trial to slow Alexander disease itself rather than manage its symptoms. In the pivotal 54-patient study, quarterly spinal injections kept treated patients walking measurably better than untreated ones at about a year. It isn't a cure, and the delivery is a lumbar puncture every 12 weeks for life. But for families who until now had only supportive care, the ceiling on this disease has moved for the first time in decades.
NewsSep 2, 2026
For an adult who can't live with a CPAP mask, the answer is starting to be yes. AD109, a once-nightly pill, is the first drug in decades of trying that credibly opens the sleeping airway. In Phase 3 trials it cut breathing interruptions by roughly 44 to 47 percent from baseline versus about 7 to 18 percent on placebo, and the FDA is set to decide on approval by February 28, 2027. It has real side effects, and no trial has yet shown it lowers heart attacks or strokes, so it's a partial fix aimed at people the mask has failed, not a replacement for a CPAP that's working.
NewsSep 1, 2026
An FDA marketing order isn't a stamp of safety. It's a bet that the strongest ZYN yet will do more good for adult smokers who switch than harm to new users it pulls in. That's why the agency cleared 11 ZYN Ultra pouches on August 21, 2026, and also why it refused to let them carry the lower-risk-than-cigarettes claim it gave 3 mg and 6 mg ZYN two months earlier. If you already smoke and can trade cigarettes fully for pouches, the deal favors you. If you don't use nicotine, Ultra is the wrong product to start on.
NewsAug 31, 2026
For severe gum disease, yes, for many people. Daily omega-3 with low-dose aspirin, added to a deep cleaning, hit the treatment goal in about the same share of patients as the standard antibiotic combo, and both roughly doubled the result of cleaning alone. Combining them added nothing. Aspirin's bleeding risk means this trade isn't for everyone, but it's a live option worth raising with your periodontist before you accept a two-week course of amoxicillin and metronidazole.
MedicationAug 30, 2026
Yes. On August 28, 2026, the FDA approved Mounjaro (tirzepatide) to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. It joins semaglutide, liraglutide, and dulaglutide as a heart-protection option in this group. What tipped the approval wasn't a lower heart-attack rate. It was fewer deaths.
Heart HealthAug 30, 2026
If you're 70 or older, a statin is worth considering when your chance of a first major cardiovascular event is high enough to make daily medication worth it. The new STAREE atorvastatin trial strengthens that case, but it doesn't turn age itself into a reason to start. It found fewer events in a broad endpoint that included cardiovascular death, nonfatal heart attack, stroke, and coronary revascularization. The reduction was driven mainly by fewer heart attacks and coronary procedures. It did not extend disability-free survival. So the useful question is personal: how much event risk are you trying to prevent?
MedicationAug 30, 2026
Yes, for most adults with polycythemia vera who depend on regular phlebotomies, a newly approved once-weekly shot can replace them. The FDA cleared Mimrylo (rusfertide) on August 28, 2026. It's an add-on to standard care, not a cure, and hasn't yet been shown to prevent clots or extend life.
